Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$9.91 +7.4%	$13.09	$9.04 ▼ $47.45	$1.12B	1.11	1.42 million shs	2.74 million shs
INDV Indivior	$9.52 +1.5%	$10.14	$7.33 ▼ $22.53	$1.31B	0.82	897,330 shs	857,967 shs
TRDA Entrada Therapeutics	$8.80 +0.5%	$11.83	$8.63 ▼ $21.79	$330.84M	-0.14	117,961 shs	167,060 shs
WVE Wave Life Sciences	$7.57 -2.2%	$10.61	$4.25 ▼ $16.74	$1.16B	-0.93	1.14 million shs	2.27 million shs

10 Stocks Set to Soar in Spring 2025

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	-11.76%	-19.04%	-32.18%	-60.82%	-67.04%
INDV Indivior	-1.57%	-2.09%	+1.52%	-24.54%	-55.40%
TRDA Entrada Therapeutics	-3.10%	-13.95%	-26.63%	-49.33%	-36.34%
WVE Wave Life Sciences	-4.21%	-18.01%	-26.77%	-37.43%	+22.66%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYN Dyne Therapeutics	3.1763 of 5 stars	4.5	1.0	0.0	2.3	4.2	0.0
INDV Indivior	3.3636 of 5 stars	3.6	3.0	0.0	2.6	1.7	1.9
TRDA Entrada Therapeutics	2.7422 of 5 stars	3.6	2.0	0.0	2.4	1.7	1.3
WVE Wave Life Sciences	4.5588 of 5 stars	3.5	3.0	4.8	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	3.07	Buy	$47.46	378.93% Upside
INDV Indivior	3.25	Buy	$15.00	57.56% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	191.67% Upside
WVE Wave Life Sciences	3.00	Buy	$22.60	198.55% Upside

Current Analyst Ratings Breakdown

Latest TRDA, INDV, DYN, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	DYN Dyne Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/7/2025	DYN Dyne Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
3/5/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
2/28/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
2/28/2025	DYN Dyne Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$53.00 ➝ $48.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
INDV Indivior	$1.19B	1.10	$1.93 per share	4.94	N/A	∞
TRDA Entrada Therapeutics	$210.78M	1.57	N/A	N/A	$7.26 per share	1.21
WVE Wave Life Sciences	$108.30M	10.73	N/A	N/A	$0.40 per share	18.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	5/1/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	5.57	N/A	-3.96%	-241.73%	15.09%	4/24/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$1.91	5.53	N/A	N/A	25.53%	16.11%	10.39%	5/6/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.79	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	5/8/2025 (Estimated)

Latest TRDA, INDV, DYN, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	INDV Indivior	$0.22	N/A	N/A	N/A	$240.13 million	N/A
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A
3/4/2025	Q4 2024	WVE Wave Life Sciences	-$0.17	$0.17	+$0.34	$0.17	$25.60 million	$83.75 million
2/27/2025	Q4 2024	TRDA Entrada Therapeutics	-$0.66	$0.03	+$0.69	$0.03	$11.95 million	$12.25 million
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	N/A	17.02	17.02
INDV Indivior	N/A	0.83	0.65
TRDA Entrada Therapeutics	N/A	6.59	6.59
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
INDV Indivior	60.33%
TRDA Entrada Therapeutics	86.39%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	20.77%
INDV Indivior	N/A
TRDA Entrada Therapeutics	7.59%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	100	113.12 million	80.63 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
TRDA Entrada Therapeutics	110	37.60 million	34.58 million	Optionable
WVE Wave Life Sciences	240	153.49 million	108.14 million	Optionable

TRDA, INDV, DYN, and WVE Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)

April 2 at 6:18 PM | markets.businessinsider.com

Wave’s Duchenne Therapy Has Promising Phase 2 Results

April 2 at 12:58 PM | managedhealthcareexecutive.com

Q1 Earnings Forecast for WVE Issued By Leerink Partnrs

April 1 at 1:17 AM | americanbankingnews.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.60 Average Price Target from Analysts

March 31 at 2:18 AM | americanbankingnews.com

What is Leerink Partnrs' Estimate for WVE Q1 Earnings?

March 31 at 1:16 AM | marketbeat.com

Loomis Sayles & Co. L P Takes $20.55 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30 at 5:18 AM | marketbeat.com

Artisan Partners Limited Partnership Trims Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

March 30 at 4:59 AM | marketbeat.com

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

March 28, 2025 | zacks.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Position Increased by Swiss National Bank

March 28, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

March 28, 2025 | marketbeat.com

WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD

March 27, 2025 | ajmc.com

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

March 27, 2025 | seekingalpha.com

Wave Life releases positive Phase II results for WVE-N531 in DMD

March 27, 2025 | thepharmaletter.com

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

March 27, 2025 | finance.yahoo.com

HC Wainwright Reaffirms Buy Rating for Wave Life Sciences (NASDAQ:WVE)

March 27, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

March 27, 2025 | marketbeat.com

Wave to submit Duchenne drug for approval after Phase 2 success

March 27, 2025 | statnews.com

Wave Life Sciences shares surge on positive DMD trial results

March 27, 2025 | investing.com

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

March 27, 2025 | zacks.com

68,927 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Quantbot Technologies LP

March 27, 2025 | marketbeat.com

Wave Life Sciences' (WVE) "Buy" Rating Reaffirmed at HC Wainwright

March 27, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
3 Companies Buying Back Stock—Why It Matters
By Gabriel Osorio-Mazilli | March 12, 2025
View 3 Companies Buying Back Stock—Why It Matters

TRDA, INDV, DYN, and WVE Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$9.91 +0.68 (+7.37%)

Closing price 04:00 PM Eastern

Extended Trading

$9.33 -0.58 (-5.85%)

As of 05:58 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Indivior NASDAQ:INDV

$9.52 +0.14 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$9.52 0.00 (0.00%)

As of 05:59 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Entrada Therapeutics NASDAQ:TRDA

$8.80 +0.04 (+0.46%)

As of 04:00 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Wave Life Sciences NASDAQ:WVE

$7.57 -0.17 (-2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$7.86 +0.29 (+3.83%)

As of 05:01 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time